Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

Dewan V, Lambert D, Edler J, Kymes S, Apte RS

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
22503301

DOI
10.1016/j.ophtha.2012.01.049

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Angiogenesis Inhibitors /economics /therapeutic use; Antibodies, Monoclonal, Humanized /economics /therapeutic use; Combined Modality Therapy; Cost-Benefit Analysis; Diabetic Retinopathy /drug therapy /economics; Female; Glucocorticoids /economics /therapeutic use; Humans; Intravitreal Injections; Laser Coagulation /economics; Macular Edema /drug therapy /economics; Male; Markov Chains; Middle Aged; Monte Carlo Method; Ranibizumab; Triamcinolone Acetonide /economics /therapeutic use; Visual Acuity

AccessionNumber
22012030563

Date bibliographic record published
14/02/2013